Pleasanton, CA 10/9/14—Roche has acquired exclusive rights to target-discovery company AbVitro’s primer-extension–based target-enrichment (PETE) technology and associated patent applications. Financial details were not disclosed. PETE technology will be used to support Roche’s next-generation sequencing (NGS) directly from blood or other biological samples. The technology will be incorporated into the Sequencing Unit’s R&D pipeline to support its NGS workflow-solutions strategy for clinical sequencing. Roche and AbVitro will collaborate on its development and application. “The potential of this technology will allow Roche to optimize our sequencing portfolio to provide a full workflow solution for our customers,” stated Dan Zabrowski, head of Roche Tissue Diagnostics and the Sequencing Unit. “We look forward to advancing this technology in order to streamline sequencing methods for easy-to-use clinical applications.”